Elon Musk’s company, Neuralink, announced on Wednesday that it has received approval to conduct its first clinical trial in Canada. The trial focuses on testing a device designed to allow individuals with paralysis to control digital devices using only their thoughts.
The company stated that the Canadian trial aims to evaluate the safety and initial performance of the brain implant, which is intended for people with quadriplegia, or paralysis affecting all four limbs, enabling them to operate external devices through mental commands.
Read more: Elon Musk Met Iran’s UN Envoy to Defuse Tensions: Report
The University Health Network hospital in Toronto has been selected to carry out the intricate neurosurgical procedures, as confirmed in a separate statement. However, Health Canada has yet to comment on the approval.
Neuralink has already tested the implant on two patients in the U.S., with positive results from the second trial participant, who has successfully used it for activities such as playing video games and learning 3D design.
Founded in 2016 by Musk and a team of engineers, Neuralink is developing a brain chip interface that can be implanted within the skull. The technology aims to assist disabled individuals by restoring mobility, improving communication, and even recovering lost vision.
In September, the company received “breakthrough device” status from the U.S. FDA for its experimental implant, which is specifically designed to restore vision.
